ABUS
Arbutus Biopharma CorpNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$813.36M
P/E Ratio
—
EPS
$-0.17
Beta
0.74
52W High
$5.10
52W Low
$2.94
50-Day MA
$4.43
200-Day MA
$4.24
Dividend Yield
—
Profit Margin
-237.90%
Forward P/E
10.25
PEG Ratio
0.00
About Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, is dedicated to the discovery, development, and commercialization of a cure for patients with chronic hepatitis B virus (HBV) infection in the United States. The company is headquartered in Warminster, Pennsylvania.
Fundamentals
| Revenue (TTM) | $14.08M |
| Gross Profit (TTM) | $-11.16M |
| EBITDA | $-26.69M |
| Operating Margin | -727.00% |
| Return on Equity | -38.50% |
| Return on Assets | -14.90% |
| Revenue/Share (TTM) | $0.07 |
| Book Value | $0.40 |
| Price-to-Book | 10.65 |
| Price-to-Sales (TTM) | 57.75 |
| EV/Revenue | 51.45 |
| EV/EBITDA | 2.68 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -33.20% |
| Shares Outstanding | $196.94M |
| Float | $125.75M |
| % Insiders | 20.52% |
| % Institutions | 64.31% |
Historical Volatility
HV 10-Day
42.96%
HV 20-Day
40.70%
HV 30-Day
45.35%
HV 60-Day
50.16%
HV Rank
42.5%
Volatility is currently contracting
Analyst Ratings
Consensus ($5.22 target)
1
Strong Buy2
BuyData last updated: 4/30/2026